STOK Stoke Therapeutics Inc

USD 9.76 -0.12 ( -1.21%)
Icon

Stoke Therapeutics Inc (STOK) Financial Statements

COMMON STOCK | Biotechnology | NSD
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 9.76

-0.12 (-1.21%)

USD 0.38B

0.58M

USD 24.08(+146.76%)

N/A

Icon

STOK

Stoke Therapeutics Inc (USD)
COMMON STOCK | NSD
USD 9.76
-0.12 ( -1.21%)

Stoke Therapeutics Inc (STOK) Annual Income Statement (USD)

STOK Quarterly Financials (USD)

Frequently Asked Questions About Stoke Therapeutics Inc (STOK) Stock

Stoke Therapeutics Inc's (STOK) last reported annual revenue was USD 36.56 Million.

Stoke Therapeutics Inc's (STOK) annual revenue growth rate based on the revenue reported in the past 5 years is : N/A

Stoke Therapeutics Inc's(STOK) is not profitable as of its last reported annual financials.

The net profit margin for Stoke Therapeutics Inc's(STOK) from its laster reported year is -243.42%

The return on equity (ROE) for Stoke Therapeutics Inc's(STOK) from its last reported annual financials is : -45.80%

The return on assets (ROA) for Stoke Therapeutics Inc's(STOK) from its last reported annual financials is : -25.35%

The return on invested capital (ROIC) for Stoke Therapeutics Inc's(STOK) from its last reported annual financials is : -6.38%

The Debt to Equity ratio for Stoke Therapeutics Inc's(STOK) from its last reported annual financials is : 0.00%

The dividend yield for Stoke Therapeutics Inc's(STOK) from its laster reported year is 0.00%

Stoke Therapeutics Inc's(STOK) has negative cash flow as of its last reported annual financials.

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...